N
#OpioidUseDisorder #PregnancyHealth #ClinicalTrial
www.nih.gov
Clinical trial results support use of weekly extended-release buprenorphine for treatment of opioid use disorder during pregnancy
NIH-supported study shows this treatment resulted in higher rates of illicit opioid abstinence than current standard of care.
#ColorectalCancer #Immunotherapy #ClinicalTrials
www.cbsnews.com
A young dad's colon cancer spread to his lungs with no warning. He says a clinical trial led to a miracle.
Kerry Breen is a news editor at CBSNews. com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital.
#SleepApnea #EpilepsyTreatment #ClinicalTrial
www.newsweek.com
Epilepsy drug could cure sleep apnea -- scientists
An epilepsy drug could be used to help people with sleep apnea, a new study has found.
A European clinical trial found that sulthiame, a drug used in the treatment of epilepsy, reduced breathing interruptions in moderate to severe obstructive sleep apnea and improved overnight oxygen levels.
N
#Alzheimers #Biomarkers #ClinicalTrials
www.nih.gov
Study measuring changes in protein structure establishes new class of Alzheimer's biomarkers
NIH-funded insights into Alzheimer's biology could help with early diagnosis, future clinical trials
In a study supported by the National Institutes of Health (NIH), researchers have identified a new type of blood-based biomarker test for Alzheimer's disease that measures structural changes in proteins, providing more information on the underlying biology of the disease than standard blood tests.
#PediatricCancer #BrainTumorResearch #ClinicalTrials
www.cbsnews.com
Colorado family prepares as funding to Pediatric Brain Tumor Consortium comes to an end
In a few days federal funding will be ending for pediatric brain tumor research, and doctors and families are wrapping up clinical trials and trying to transition the lifesaving work elsewhere.
#HIV #Healthcare #ClinicalTrials
www.yahoo.com
ViiV's four-monthly HIV drug maintains viral suppression at 12 months
Add Yahoo as a preferred source to see more of our stories on Google.
ViiV Healthcare's investigational four-monthly HIV drug maintains viral suppression at 12 months in a Phase IIb trial.
#VisionRestoration #EyeHealth #ClinicalTrials
www.forbes.com
A New Era For Blindness Treatment Is Within Sight
Seeing is believing. For patients in clinical trials for eye diseases, that truism is literal.
From stem cells to bionic vision implants, there's never been a more exciting time for novel approaches to treating devastating eye conditions.
#glioblastoma #brainhealth #clinicaltrials
www.cbsnews.com
Woman shares unlikely survival journey after migraines led to glioblastoma diagnosis: "I am truly an outlier"
Kerry Breen is a news editor at CBSNews. com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital.
#glioblastoma #cancerresearch #clinicaltrials
www.cbsnews.com
Woman shares unlikely survival journey after migraines led to glioblastoma diagnosis: "I am truly an outlier"
Kerry Breen is a news editor at CBSNews. com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital.
U
#ADHD #ClinicalTrials #MentalHealth
www.usnews.com
FDA-Approved Nerve Stimulation Device For ADHD Is Ineffective, Clinical Trial Concludes
By Dennis Thompson HealthDay ReporterTUESDAY, Jan. 20, 2026 (HealthDay News) -- A U. S. Food and Drug Administration (FDA)-approved device for treating ADHD in kids simply doesn't work, a new clinical trial says.
#Biotechnology #AutoimmuneDiseases #ClinicalTrials
www.nasdaq.com
Jade Biosciences To Report Phase I Trial Of JADE101 In 1H2026
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, announced its 2026 strategic priorities on Monday, including anticipated milestones before the 44th Annual J.
#Neuroscience #Alzheimers #ClinicalTrials
www.nasdaq.com
NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study
(RTTNews) - Neumora Therapeutics, Inc. (NMRA) has entered 2026 with momentum, announcing positive Phase 1b results for its lead candidate NMRA-511 in Alzheimer's disease agitation, along with a pipeline strategy that promises multiple clinical readouts across its neuroscience programs.
#NeumoraTherapeutics #Alzheimers #ClinicalTrials
www.nasdaq.com
Neumora Therapeutics Reports Encouraging Phase 1b Data For NMRA-511 In Alzheimer's Disease Agitation
(RTTNews) - Neumora Therapeutics, Inc. (NMRA) on Monday announced positive results from a Phase 1b study of NMRA-511 in patients with agitation associated with Alzheimer's disease (AD).
#Osteoporosis #Biotech #ClinicalTrials
www.benzinga.com
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
- Company expects topline data from the study in 2027
WESTLAKE VILLAGE, Calif.
#Biopharma #Neuroscience #ClinicalTrials
www.benzinga.com
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Neumora Therapeutics (NASDAQ:NMRA)
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation
KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026
Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model
Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score
Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027
WATERTOWN, Mass.
#biopharmaceuticals #cancerresearch #clinicaltrials
www.nasdaq.com
HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer
(RTTNews) - HUTCHMED (China) Ltd (HCM, HCM. L,0013. HK), a commercial-stage, biopharmaceutical company, announced on Monday that it has commenced the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib combined with camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma or PDAC in China.
#Pharmaceuticals #ClinicalTrials #DrugDevelopment
www.nasdaq.com
Crinetics To Provide Update On PALSONIFY And Topline Results From Phase 2 Trial Of Atumelnant In CAH
(RTTNews) - Crinetics Pharmaceuticals, Inc. (CRNX) is scheduled to host a conference call to provide an update on its lead drug PALSONIFY's commercialisation and disclose topline results from the fourth cohort of its Phase 2 trial of Atumelnant in congenital adrenal hyperplasia or CAH, today.
